IMRX — Immuneering Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1790340 ·
Last close
$5.18
Market Cap
$335.13M
52W High
$5.95
52W Low
$3.86
ADV30
696,147
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,999,964 | -17,270,427 | 202,055,327 | 41,324,682 | 11,320,301 |
| Mar 2026 | 0 | — | -15,334,539 | -13,460,895 | 214,809,790 | 47,321,566 | 8,291,619 |
| Dec 2025 | 0 | — | -13,751,943 | -11,580,010 | 231,985,010 | 128,645,025 | 13,501,042 |
| Sep 2025 | 0 | — | -15,380,300 | -14,964,875 | 241,056,266 | 227,563,077 | 13,079,834 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,752,670
Investing CF
$-141,318,060
Financing CF
$213,039,914
CapEx
$-238,462
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-311,051,406
Inventory
—
Receivables
—
ST Investments
$108,575,637
EBIT TTM
$-63,466,746
Pretax Income TTM
$-57,274,086
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,375,728 | -56,024,898 | 231,985,010 | 13,501,042 | — | -45,344,595 |
| Dec 2024 | 0 | -64,071,655 | -61,036,608 | 52,714,413 | 11,328,187 | — | -54,999,571 |
| Dec 2023 | 0 | -58,413,285 | -53,471,622 | 102,584,538 | 12,008,355 | — | -48,968,634 |
| Dec 2022 | 316,952 | -51,745,339 | -50,513,568 | 122,367,283 | 12,517,028 | — | -44,101,265 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,751,499
NetIncome TTM
$-53,234,615
OpCashFlow TTM
$0
Assets (Latest)
$52,714,413
Forward EPS
$-1.29
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $5.18 · call volume: 170 · put volume: 110
Expected Move to 2027-01-15:
±$2.10
(40.54%) —
implied range
$3.08 –
$7.28
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | $335.28M | $4.03 | — |
| PRE | Prenetics Global Ltd | $331.63M | $21.82 | — |
| PRQR | ProQR Therapeutics N.V. | $342.92M | $2.43 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $346.54M | $6.06 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $322.27M | $5.33 | — |
News headlines (Yahoo Finance, 1h cache)
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-05 11:30 · Yahoo
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
2026-07-21 20:05 · Yahoo
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
2026-07-15 16:00 · Yahoo
Immuneering Appoints Andrew Gengos as Chief Financial Officer
2026-06-15 11:30 · Yahoo
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
2026-06-01 11:30 · Yahoo
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-15 11:35 · Yahoo
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
2026-05-06 14:53 · Yahoo
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
2026-04-20 13:00 · Yahoo
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-06 20:05 · Yahoo
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
2026-06-12 13:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.